Stockreport

Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the developmen [Read more]